Exelixis (EXEL) Income from Continuing Operations (2010 - 2026)
Exelixis (EXEL) recorded quarterly Income from Continuing Operations of 210467000.0 in Q2 2026, down 13.93% quarter-over-quarter from 244528000.0 in Q1 2026, and up 31.86% on a YoY basis from 159616000.0 in Q2 2025.
Exelixis (EXEL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Exelixis' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 210467000.0 for Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 31.86% year-over-year to 210467000.0; the TTM figure through Apr 2026 stood at 833421000.0 (up 29.5% YoY), while the FY2026 annual figure was 782570000.0, up 50.13% from the prior year.
- Income from Continuing Operations was 210467000.0 for Q2 2026 at Exelixis, down from 244528000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 244528000.0 in Q1 2026 to a low of 30173000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 112020647.06 across 5 years, with a median of 85518000.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations plunged 131.71% in 2022, then jumped 11232.66% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 30173000.0 in 2022, then surged by 383.43% to 85518000.0 in 2023, then jumped by 37.95% to 117973000.0 in 2024, then jumped by 64.09% to 193578000.0 in 2025, then increased by 8.72% to 210467000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 210467000.0 (Q2 2026), 244528000.0 (Q1 2026), and 193578000.0 (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | 210.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 210.47 Mn |
| Jan 2, 2026 | 244.53 Mn |
| Oct 3, 2025 | 193.58 Mn |
| Jul 4, 2025 | 184.85 Mn |
| Apr 4, 2025 | 159.62 Mn |
| Jan 3, 2025 | 139.86 Mn |
| Sep 27, 2024 | 117.97 Mn |
| Jun 28, 2024 | 226.12 Mn |
| Mar 29, 2024 | 37.32 Mn |
| Dec 29, 2023 | 85.52 Mn |
| Sep 29, 2023 | 1.04 Mn |
| Jun 30, 2023 | 81.18 Mn |
| Mar 31, 2023 | 40.03 Mn |
| Dec 30, 2022 | -30.17 Mn |
| Sep 30, 2022 | 73.21 Mn |
| Jul 1, 2022 | 70.67 Mn |
| Apr 1, 2022 | 68.57 Mn |
| Dec 31, 2021 | 95.17 Mn |
| Oct 1, 2021 | 38.20 Mn |
| Jul 2, 2021 | 96.09 Mn |